With 3 days of tailored content, 20+ expert speakers from Regeneron, Amgen, IGM Bioscience, and more met to dive deep into the progress of immunotherapy medicines in precision oncology tactics.
The 5th Annual Cell Engager Summit was the leading and only event to fully focus on the translational and clinical challenges of cell engager therapeutics including bispecific t-cell engagers, gamma delta engagers, innate killer engagers, and T-cell engagers.
Bringing together this community was pivotal in the development of the space, with so many positive readouts, approvals, and collaborations we must join forces to improve the back translation as we learnt from our clinical successes and failures to influence benchwork.
You missed out on the annual gathering on pharma, biotech, and academia as they discuss cytokine release syndrome, maximizing translation with a focus on the hottest targets in the space all to maximize the therapeutic window of cell engager therapeutics.
3 Unmissable Highlights Included:
Deep dive into novel cell engager types with Kate Rochlin, Chief Operations Officer, IN8 Bio as she lead us through a focussed analysis of Gamma Delta Cell biology and therapeutic principles
Gained a comprehensive understanding of NK engagement including how they offered enhanced tumor killing potential as well as what potential combinations could enhance them with Tony Arulanandam, Vice President & Head of Preclinical at Cytovia Therapeutics and Louise Koopman, Senior Scientist at Genmab
Get stuck in with 3 different types of interactive sessions on the main conference agenda! These sessions include, a roundtable assessing solid tumor response strategies, an interactive worksheet activity - “co-engage, co-stimulate or combine” and our scientific poster session
Hear What Past Attendees Have Said:
"Great opportunity to meet scientists who think about TCEs for a living" - Cullinan Oncology
"Excellent insight into extremely hot and competitive space" - Link
"Engaging science and a variety of strong presentations and discussions highlighting innovative approaches that are being implemented and tested in the rapidly developing field of bispecifics" - Eli Lilly